Wheadon David E. 4

What Happened David E. Wheadon, a director of Indivior Pharmaceuticals, was granted 5,955 restricted stock units (RSUs) on January 26, 2026. The reported acquisition price is $0.00 (i.e., no immediate cash outlay); the filing lists the transaction as an award/grant (code A). These RSUs represent a contingent right to receive one share of Indivior common stock per RSU upon vesting.

Key Details

• Transaction date: 2026-01-26; Form 4 filed: 2026-01-28 (timely, within the usual two-business-day window).
• Award: 5,955 RSUs; reported acquisition price $0.00 (total immediate reported value $0).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: RSUs vest on the day immediately preceding the date of the first annual meeting of stockholders following the grant, contingent on Mr. Wheadon’s continued service (see footnote F1).
• Transaction code: A = Award/Grant.

Context RSU grants are a common form of long-term compensation for directors and are contingent on future vesting conditions — they are not an immediate purchase of stock and do not necessarily indicate a personal bullish or bearish view. Because these RSUs vest only if Mr. Wheadon remains in service through the specified vesting date, the award mainly reflects standard compensation practices rather than an immediate change in insider holdings.